SCHEMBL1492349

SCHEMBL1492349

CCOC(=O)c1[nH]ccc1NC(=O)Cc1ccc(F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.53
MEN1 O00255 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
KDM4E B2RXH2 3/20 0.53
ALDH1A1 P00352 2/20 0.53
GAA P10253 2/20 0.48
MAPK1 P28482 1/20 0.47
POLB P06746 3/20 0.46
TP53 P04637 1/20 0.46
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
MAPK8 P45983 1/20 0.46
MAPK9 P45984 1/20 0.46
MAPK10 P53779 1/20 0.46
ALOX15 P16050 1/20 0.44
HPGD P15428 1/20 0.44
MAPT P10636 2/20 0.43
CASP3 P42574 1/20 0.43
TRPV1 Q8NER1 1/20 0.43
SENP7 Q9BQF6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1492403 0.87 SMN1; SMN2 (0.54) KMT2AMEN1SMN1; SMN2KDM4EALDH1A1
SCHEMBL31735479 0.83 POLB (0.57) KMT2AMEN1ALDH1A1GAAPOLB
SCHEMBL25241521 0.82 KDM4E (0.51) KMT2AMEN1KDM4EALDH1A1GAA
SCHEMBL1492325 0.77 KDM4E (0.50) KMT2AMEN1SMN1; SMN2KDM4EALDH1A1
SCHEMBL4200796 0.76 ALDH1A1 (0.45) KMT2AMEN1SMN1; SMN2KDM4EALDH1A1
SCHEMBL2626729 0.73 KMT2A (0.44) KMT2AMEN1SMN1; SMN2KDM4EALDH1A1
SCHEMBL10293979 0.73 GAA (0.53) KMT2AMEN1SMN1; SMN2KDM4EALDH1A1
SCHEMBL16828410 0.72 PRKCZ (0.51) KMT2AMEN1SMN1; SMN2KDM4EALDH1A1
SCHEMBL16236949 0.72 KDM4E (0.46) KMT2AMEN1SMN1; SMN2KDM4EALDH1A1
SCHEMBL4393322 0.72 KDM4E (0.41) KMT2AMEN1SMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2475660-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GlaxoSmithKline LLC (US) 2012-07-18 EP disclosed
US-20120172333-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2012-07-05 US disclosed
WO-2011029855-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2011-03-17 WO disclosed
WO-2011029855-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2011-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172333-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK PRKAB1, PRKAG1, PRKAB2 KMT2A 2761/4885MEN1 4029/4885SMN1; SMN2 4359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.